Cargando…

Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: Secondary data analysis of a prospective recruited cohort

BACKGROUND: The association of vitamin D deficiency, which is prevalent in type 2 diabetes mellitus (T2DM), with liver disease and related mortality has not been quantified. Our study aimed to (1) investigate whether there is a synergistic association of vitamin D deficiency and T2DM with liver-rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu, Dan, Lintao, Fu, Tian, Sun, Yuhao, Chen, Jie, Mao, Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617905/
https://www.ncbi.nlm.nih.gov/pubmed/37902501
http://dx.doi.org/10.1097/HC9.0000000000000291
_version_ 1785129674559455232
author Wang, Yu
Dan, Lintao
Fu, Tian
Sun, Yuhao
Chen, Jie
Mao, Ren
author_facet Wang, Yu
Dan, Lintao
Fu, Tian
Sun, Yuhao
Chen, Jie
Mao, Ren
author_sort Wang, Yu
collection PubMed
description BACKGROUND: The association of vitamin D deficiency, which is prevalent in type 2 diabetes mellitus (T2DM), with liver disease and related mortality has not been quantified. Our study aimed to (1) investigate whether there is a synergistic association of vitamin D deficiency and T2DM with liver-related outcomes and (2) explore whether high 25-hydroxyvitamin D [25(OH)D] concentrations are associated with a lower risk of liver-related outcomes in T2DM. METHOD: Leveraging the data from UK Biobank, we conducted 2 studies: study I assessed the joint associations of vitamin D deficiency [25(OH)D <50 nmol/L] and T2DM with liver-related outcomes among 439,276 participants, and study II explored the associations of vitamin D status with liver-related outcomes among 21,519 individuals with T2DM. Baseline T2DM was identified through medication, laboratory test, and electronic health-related records. Serum 25(OH)D was measured by direct competitive chemiluminescent immunoassay. Liver-related outcomes included 6 liver disease end points and mortality by overall liver disease, chronic liver disease, and severe liver disease. RESULTS: During an average follow-up duration of 11.6 years, we observed a significant positive additive interaction effect (all synergy index>1.0) of T2DM and vitamin D deficiency on the risk of liver-related outcomes. Compared with participants without either T2DM or vitamin D deficiency, the multivariable-adjusted HRs of overall liver diseases were 1.29 for participants without T2DM but with vitamin D deficiency, 1.73 for participants with T2DM but without vitamin D deficiency, and 2.19 for participants with both T2DM and vitamin D deficiency. In individuals with T2DM, we observed that participants without vitamin D deficiency were inversely associated with incident liver disease and related mortality (multivariable-adjusted HRs 0.41–0.81) when compared with individuals with vitamin D deficiency. CONCLUSIONS: There are positive synergistic associations of vitamin D deficiency and T2DM with liver-related outcomes. Inverse associations between serum 25(OH)D concentrations and liver-related outcomes were observed in individuals with T2DM.
format Online
Article
Text
id pubmed-10617905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106179052023-11-01 Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: Secondary data analysis of a prospective recruited cohort Wang, Yu Dan, Lintao Fu, Tian Sun, Yuhao Chen, Jie Mao, Ren Hepatol Commun Original Article BACKGROUND: The association of vitamin D deficiency, which is prevalent in type 2 diabetes mellitus (T2DM), with liver disease and related mortality has not been quantified. Our study aimed to (1) investigate whether there is a synergistic association of vitamin D deficiency and T2DM with liver-related outcomes and (2) explore whether high 25-hydroxyvitamin D [25(OH)D] concentrations are associated with a lower risk of liver-related outcomes in T2DM. METHOD: Leveraging the data from UK Biobank, we conducted 2 studies: study I assessed the joint associations of vitamin D deficiency [25(OH)D <50 nmol/L] and T2DM with liver-related outcomes among 439,276 participants, and study II explored the associations of vitamin D status with liver-related outcomes among 21,519 individuals with T2DM. Baseline T2DM was identified through medication, laboratory test, and electronic health-related records. Serum 25(OH)D was measured by direct competitive chemiluminescent immunoassay. Liver-related outcomes included 6 liver disease end points and mortality by overall liver disease, chronic liver disease, and severe liver disease. RESULTS: During an average follow-up duration of 11.6 years, we observed a significant positive additive interaction effect (all synergy index>1.0) of T2DM and vitamin D deficiency on the risk of liver-related outcomes. Compared with participants without either T2DM or vitamin D deficiency, the multivariable-adjusted HRs of overall liver diseases were 1.29 for participants without T2DM but with vitamin D deficiency, 1.73 for participants with T2DM but without vitamin D deficiency, and 2.19 for participants with both T2DM and vitamin D deficiency. In individuals with T2DM, we observed that participants without vitamin D deficiency were inversely associated with incident liver disease and related mortality (multivariable-adjusted HRs 0.41–0.81) when compared with individuals with vitamin D deficiency. CONCLUSIONS: There are positive synergistic associations of vitamin D deficiency and T2DM with liver-related outcomes. Inverse associations between serum 25(OH)D concentrations and liver-related outcomes were observed in individuals with T2DM. Lippincott Williams & Wilkins 2023-10-31 /pmc/articles/PMC10617905/ /pubmed/37902501 http://dx.doi.org/10.1097/HC9.0000000000000291 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Article
Wang, Yu
Dan, Lintao
Fu, Tian
Sun, Yuhao
Chen, Jie
Mao, Ren
Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: Secondary data analysis of a prospective recruited cohort
title Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: Secondary data analysis of a prospective recruited cohort
title_full Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: Secondary data analysis of a prospective recruited cohort
title_fullStr Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: Secondary data analysis of a prospective recruited cohort
title_full_unstemmed Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: Secondary data analysis of a prospective recruited cohort
title_short Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: Secondary data analysis of a prospective recruited cohort
title_sort serum 25-hydroxyvitamin d, type 2 diabetes, and liver-related outcomes: secondary data analysis of a prospective recruited cohort
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617905/
https://www.ncbi.nlm.nih.gov/pubmed/37902501
http://dx.doi.org/10.1097/HC9.0000000000000291
work_keys_str_mv AT wangyu serum25hydroxyvitamindtype2diabetesandliverrelatedoutcomessecondarydataanalysisofaprospectiverecruitedcohort
AT danlintao serum25hydroxyvitamindtype2diabetesandliverrelatedoutcomessecondarydataanalysisofaprospectiverecruitedcohort
AT futian serum25hydroxyvitamindtype2diabetesandliverrelatedoutcomessecondarydataanalysisofaprospectiverecruitedcohort
AT sunyuhao serum25hydroxyvitamindtype2diabetesandliverrelatedoutcomessecondarydataanalysisofaprospectiverecruitedcohort
AT chenjie serum25hydroxyvitamindtype2diabetesandliverrelatedoutcomessecondarydataanalysisofaprospectiverecruitedcohort
AT maoren serum25hydroxyvitamindtype2diabetesandliverrelatedoutcomessecondarydataanalysisofaprospectiverecruitedcohort